Avoro Capital Advisors’s ImmunityBio IBRX Stock Holding History

Avoro Capital Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-72,412	Closed	-$563K	–	45
2016 Q3	$563K	Hold	72,412	–	–	0.1%	43
2016 Q2	$450K	Sell	72,412 -122,500	-63%	-$951K	0.1%	38
2016 Q1	$1.6M	Sell	194,912 -404,375	-67%	-$3.81M	0.56%	29
2015 Q4	$8.83M	Sell	599,287 -129,600	-18%	-$1.92M	3.04%	14
2015 Q3	$7.3M	Buy	+728,887	New	+$15.9M	1.9%	17

Other funds holding IBRX

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avoro Capital Advisors's IBRX Position: Q4 2016 in Review

Avoro Capital Advisors sold out of ImmunityBio (IBRX) in Q4 2016, closing a stake of 72,412 shares — an estimated $563K sold.

Avoro Capital Advisors first reported a position in IBRX in Q3 2015 and held it in 5 quarters. The position peaked at $8.83M in Q4 2015. 68 funds tracked by Wall St. Rank hold IBRX as of Q4 2016.

Avoro Capital Advisors reported no remaining ImmunityBio position as of Q4 2016 after selling out during the quarter.
Avoro Capital Advisors sold 72,412 ImmunityBio shares in Q4 2016, an estimated $563K.
Avoro Capital Advisors first reported a position in ImmunityBio in Q3 2015 and held it in 5 quarters.
Avoro Capital Advisors's ImmunityBio position peaked at $8.83M in Q4 2015.
68 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2016.

Based on Avoro Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.